Compare · GILD vs VCEL
GILD vs VCEL
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $157.96B, about 80.4x VCEL ($1.96B).
- Over the past year, GILD is up 14.8% and VCEL is down 7.6% - GILD leads by 22.4 points.
- GILD has been more active in the news (18 items in the past 4 weeks vs 3 for VCEL).
- GILD has more recent analyst coverage (25 ratings vs 11 for VCEL).
- Company
- Gilead Sciences Inc.
- Vericel Corporation
- Price
- $127.25+2.40%
- $38.44+0.42%
- Market cap
- $157.96B
- $1.96B
- 1M return
- -1.81%
- +16.38%
- 1Y return
- +14.83%
- -7.62%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 18
- 3
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest GILD
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)
- National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
Latest VCEL
- The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
- Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
- Chief Medical Officer Hopper Jonathan Mark exercised 4,375 shares at a strike of $16.66 and sold $153,125 worth of shares (4,375 units at $35.00) as part of a pre-agreed trading plan (SEC Form 4)
- The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
- Vericel Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $7.84 and sold $229,775 worth of shares (7,000 units at $32.83) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wotton Paul K sold $327,425 worth of shares (10,000 units at $32.74), decreasing direct ownership by 35% to 18,802 units (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr sold $202,500 worth of shares (5,000 units at $40.50) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 21,009 units (SEC Form 4)
- Principal Accounting Officer Siegal Jonathan sold $188,045 worth of shares (4,855 units at $38.73) as part of a pre-agreed trading plan, decreasing direct ownership by 81% to 1,118 units (SEC Form 4)
- SEC Form 10-Q filed by Vericel Corporation